Clinical Trial Update: A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) [Phase 3]

View source ↗

Summary

Phase 3 ATTAIN-MAINTAIN evaluated Orforglipron for maintenance of body weight reduction in adults with obesity or overweight and weight-related comorbidities. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: COMPLETED